Identification of PANoptosis-related signature reveals immune infiltration characteristics and immunotherapy responses for renal cell carcinoma

被引:4
作者
Xu, Yan [1 ]
Hua, Jingqi [2 ]
Que, Hongliang [2 ]
Zeng, Tengyue [2 ]
Li, Quan [2 ]
Deng, Junpeng [2 ]
Xie, Jianjun [2 ]
机构
[1] China Med Univ, Hosp 1, Dept Urol, Shenyang 110001, Peoples R China
[2] Suzhou Municipal Hosp, Dept Urol, Suzhou 215001, Peoples R China
关键词
PANoptosis; Clear cell renal cell carcinoma; Papillary renal cell carcinoma; Chromophobe renal cell carcinoma; Tumor microenvironment; Immunotherapy; NF-KAPPA-B; ADAPTER; ASC;
D O I
10.1186/s12885-024-12067-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PANoptosis is a specific type of inflammatory programmed cell death (PCD) modality that can be involved in three key modes of cellular programmed cell death-pyroptosis, apoptosis and necroptosis. We analyzed PANoptosis activity in three common renal cell carcinoma subtypes (Clear cell renal cell carcinoma, Papillary renal cell carcinoma, and Chromophobe renal cell carcinoma) separately and constructed a new PANoptosis immunity index (PANII). In three renal cell carcinomas, we found that PANII was an effective predictor of immunotherapy efficacy in KIRC, KIRP and KICH, and the high PANII group was characterized by high immune infiltration and sensitivity to immunotherapy, while the low PANII group was prone to immune escape and immunotherapy resistance. We performed molecular docking prediction of each core protein comprising PANII and identified natural small molecule compounds with the highest affinity to target proteins. In addition, we found that down-regulation of PYCARD inhibited the proliferation and migration of renal clear cell carcinoma cells by in vitro functional assays, suggesting that PYCARD could be a novel target for renal clear cell carcinoma therapy. Our findings that the PANoptosis characterization-based index (PANII) helps to elucidate the tumor microenvironmental features of three common renal cell carcinoma subtypes and identify patient populations that will benefit from immunotherapy, providing a new tool for the clinical diagnosis and treatment of patients with intermediate- and advanced-stage renal cell carcinoma.
引用
收藏
页数:13
相关论文
共 41 条
  • [11] Bi-Phase Evolutionary Searching for Biclusters in Gene Expression Data
    Huang, Qinghua
    Huang, Xianhai
    Kong, Zhoufan
    Li, Xuelong
    Tao, Dacheng
    [J]. IEEE TRANSACTIONS ON EVOLUTIONARY COMPUTATION, 2019, 23 (05) : 803 - 814
  • [12] Parallelized Evolutionary Learning for Detection of Biclusters in Gene Expression Data
    Huang, Qinghua
    Tao, Dacheng
    Li, Xuelong
    Liew, Alan Wee-Chung
    [J]. IEEE-ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS, 2012, 9 (02) : 560 - 570
  • [13] Caspase-8: A key protein of cross-talk signal way in "PANoptosis" in cancer
    Jiang, Mingxia
    Qi, Ling
    Li, Lisha
    Wu, Yiming
    Song, Dongfeng
    Li, Yanjing
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (07) : 1408 - 1420
  • [14] Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
    Jiang, Minlin
    Jia, Keyi
    Wang, Lei
    Li, Wei
    Chen, Bin
    Liu, Yu
    Wang, Hao
    Zhao, Sha
    He, Yayi
    Zhou, Caicun
    [J]. ACTA PHARMACEUTICA SINICA B, 2021, 11 (10) : 2983 - 2994
  • [15] Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
    Jiang, Peng
    Gu, Shengqing
    Pan, Deng
    Fu, Jingxin
    Sahu, Avinash
    Hu, Xihao
    Li, Ziyi
    Traugh, Nicole
    Bu, Xia
    Li, Bo
    Liu, Jun
    Freeman, Gordon J.
    Brown, Myles A.
    Wucherpfennig, Kai W.
    Liu, X. Shirley
    [J]. NATURE MEDICINE, 2018, 24 (10) : 1550 - +
  • [16] AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence
    Lee, SangJoon
    Karki, Rajendra
    Wang, Yaqiu
    Nguyen, Lam Nhat
    Kalathur, Ravi C.
    Kanneganti, Thirumala-Devi
    [J]. NATURE, 2021, 597 (7876) : 415 - +
  • [17] Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma
    Liang, Xiaowei
    Gao, Hongwei
    Xiao, Jian
    Han, Shan
    He, Jia
    Yuan, Renyikun
    Yang, Shilin
    Yao, Chun
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [18] An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
    Liu, Jianfang
    Lichtenberg, Tara
    Hoadley, Katherine A.
    Poisson, Laila M.
    Lazar, Alexander J.
    Cherniack, Andrew D.
    Kovatich, Albert J.
    Benz, Christopher C.
    Levine, Douglas A.
    Lee, Adrian V.
    Omberg, Larsson
    Wolf, Denise M.
    Shriver, Craig D.
    Thorsson, Vesteinn
    Hu, Hai
    [J]. CELL, 2018, 173 (02) : 400 - +
  • [19] Innate immune priming in the absence of TAK1 drives RIPK1 kinase activity-independent pyroptosis, apoptosis, necroptosis, and inflammatory disease
    Malireddi, R. K. Subbarao
    Gurung, Prajwal
    Kesavardhana, Sannula
    Samir, Parimal
    Burton, Amanda
    Mummareddy, Harisankeerth
    Vogel, Peter
    Pelletier, Stephane
    Burgula, Sandeepta
    Kanneganti, Thirumala-Devi
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2020, 217 (03)
  • [20] Laminaran from brown alga Dictyota dichotoma and its sulfated derivative as radioprotectors and radiosensitizers in melanoma therapy
    Malyarenko, Olesya S.
    Usoltseva, Roza V.
    Zvyagintseva, Tatyana N.
    Ermakova, Svetlana P.
    [J]. CARBOHYDRATE POLYMERS, 2019, 206 : 539 - 547